Plasma β-Amyloid in Mild Behavioural Impairment - Neuropsychiatric Symptoms on the Alzheimer's Continuum
Autor: | James Naude, Ruxin Miao, Eric Smith, Zahinoor Ismail, Hung-Yu Chen, Sascha Gill |
---|---|
Rok vydání: | 2021 |
Předmět: |
medicine.medical_specialty
Neuropsychological Tests 03 medical and health sciences 0302 clinical medicine β amyloid Normal cognition Alzheimer Disease Internal medicine medicine Dementia Humans Cognitive Dysfunction Continuum (set theory) Cognitive decline Cognitive impairment Beta (finance) Aged Amyloid beta-Peptides 030214 geriatrics Continuum (measurement) business.industry Neurodegenerative Diseases medicine.disease Psychiatry and Mental health Endocrinology Neurology (clinical) Geriatrics and Gerontology Alzheimer's disease business Neuroscience 030217 neurology & neurosurgery Biomarkers |
Zdroj: | Journal of geriatric psychiatry and neurology. 35(3) |
ISSN: | 0891-9887 |
Popis: | IntroductionSimple markers are required to recognize older adults at higher risk for neurodegenerative disease. Mild behavioural impairment (MBI) and plasma β-amyloid (Aβ) have been independently implicated in the development of incident cognitive decline and dementia. Here we studied the associations between MBI and plasma Aβ42/Aβ40.MethodsParticipants with normal cognition (n = 86) or mild cognitive impairment (n = 53) were selected from the Alzheimer’s Disease Neuroimaging Initiative. MBI scores were derived from Neuropsychiatric Inventory items. Plasma Aβ42/Aβ40 ratios were assayed using mass spectrometry. Linear regressions were fitted to assess the association between MBI total score as well as MBI domain scores with plasma Aβ42/Aβ40.ResultsLower plasma Aβ42/Aβ40 was associated with higher MBI total score (p = 0.04) and greater affective dysregulation (p = 0.04), but not with impaired drive/motivation (p = 0.095) or impulse dyscontrol (p = 0.29) MBI domains.ConclusionIn persons with normal cognition or mild cognitive impairment, MBI was associated with low plasma Aβ42/Aβ40. Incorporating MBI into case detection can help capture preclinical and prodromal Alzheimer’s disease. |
Databáze: | OpenAIRE |
Externí odkaz: |